Pre-exposure prophylaxis for preventing acquisition of HIV: A cross-sectional study of patients, prescribers, uptake, and spending in the United States, 2015-2016.
Stephanie S ChanAndre R ChappelKaren E Joynt MaddoxKaren W HooverYa-Lin A HuangWeiming ZhuStacy M CohenPamela W KleinNancy De LewPublished in: PLoS medicine (2020)
Our findings indicate that in 2015-2016, many individuals in the US who could benefit from being on PrEP were not receiving this HIV prevention medication, and those prescribed PrEP had a significantly different distribution of characteristics from the broader population that is at risk for acquiring HIV. PrEP patients were more likely to pay for PrEP using commercial or private insurance, whereas PLWH were more likely to pay for their antiretroviral treatment using publicly sponsored programs. Addressing the affordability of PrEP and otherwise promoting its use among those with indications for PrEP represents an important opportunity to help end the HIV epidemic.
Keyphrases
- men who have sex with men
- hiv positive
- hiv testing
- hiv infected
- human immunodeficiency virus
- antiretroviral therapy
- end stage renal disease
- hiv aids
- hepatitis c virus
- chronic kidney disease
- newly diagnosed
- healthcare
- prognostic factors
- public health
- patient reported outcomes
- hiv infected patients
- emergency department
- south africa